Equities

Suven Pharmaceuticals Ltd

SUVENPHAR:NSI

Suven Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,295.15
  • Today's Change19.20 / 1.50%
  • Shares traded608.33k
  • 1 Year change+112.32%
  • Beta1.6567
Data delayed at least 15 minutes, as of Nov 22 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The one analyst offering a 12 month price target expects Suven Pharmaceuticals Ltd share price to rise to 1,330.00 in the next year from the last price of 1,284.65.
High3.5%1,330.00
Med3.5%1,330.00
Low3.5%1,330.00

Dividends

Historical dividend information is not available for Suven Pharmaceuticals Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On Feb 06, 2023, earnings of 4.23 per share.
The next earnings announcement is expected on May 28, 2025.
Average growth rate-1.78%
Suven Pharmaceuticals Ltd reported annual 2024 earnings of 11.80 per share on May 30, 2024.
Average growth rate-3.68%
More ▼

Revenue history & estimates in INR

Suven Pharmaceuticals Limited had 2nd quarter 2025 revenues of 2.58bn. This bettered the 2.08bn estimate of the one analyst covering the company. This was 25.85% below the prior year's 2nd quarter results.
Average growth rate+3.28%
Suven Pharmaceuticals Limited had revenues for the full year 2024 of 10.51bn. This was 21.56% below the prior year's results.
Average growth rate+7.95%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.